Ja, Roche er jo intressert i RIT, det vet vi av avtalen de laget med ArevaMed i sin tid. I tillegg har Roche det et produkt i pipelinen der også.
Roche and AREVA Med join forces in the fight against cancer and create a novel radio-immunotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY) and AREVA Med, a subsidiary of AREVA, announced today that they have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. The agreement will focus on malignant disease with a high unmet medical need.
Under this exclusive agreement, Roche’s Pharma Research and Early Development (pRED) organization and AREVA Med will assess the efficacy of combining Roche-engineered antibodies with AREVA Med’s radionuclide, Lead-212, a compound that shows promise in treating some types of cancer. Roche retains exclusive rights to commercialise the cancer radio-immunotherapy after clinical development. The alliance combines Roche’s expertise in engineered antibodies with AREVA Med’s proficiency in developing radioactive isotopes.
https://www.roche.com/media/releases/med-cor-2012-07-27p.htm